Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.47
0.00 (0.00%)
Dec 5, 2025, 4:00 PM EST - Market closed
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Trevi Therapeutics stock have an average target of 20.59, with a low estimate of 12.5 and a high estimate of 27. The average target predicts an increase of 52.86% from the current stock price of 13.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Trevi Therapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $13 → $16 | Buy | Maintains | $13 → $16 | +18.78% | Nov 20, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $19 | Strong Buy | Maintains | $19 | +41.05% | Nov 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $23 → $24 | Buy | Maintains | $23 → $24 | +78.17% | Nov 14, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $18 → $19 | Buy | Maintains | $18 → $19 | +41.05% | Nov 14, 2025 |
| Clear Street | Clear Street | Strong Buy Maintains $11 → $21 | Strong Buy | Maintains | $11 → $21 | +55.90% | Nov 14, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.37
from -0.47
EPS Next Year
-0.47
from -0.37
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.37 | -0.23 | ||||
| Avg | -0.37 | -0.47 | ||||
| Low | -0.40 | -0.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.